Loading...
XNYS
WAT
Market cap17bUSD
Jul 31, Last price  
288.76USD
1D
-3.45%
1Q
-17.60%
Jan 2017
114.87%
Name

Waters Corp

Chart & Performance

D1W1MN
P/E
26.95
P/S
5.81
EPS
10.72
Div Yield, %
Shrs. gr., 5y
-2.67%
Rev. gr., 5y
4.22%
Revenues
2.96b
+0.07%
1,158,236,0001,280,229,0001,473,048,0001,575,124,0001,498,700,0001,643,371,0001,851,184,0001,843,641,0001,904,218,0001,989,344,0002,042,332,0002,167,423,0002,309,078,0002,419,929,0002,406,596,0002,365,365,0002,785,874,0002,971,956,0002,956,416,0002,958,387,000
Net income
638m
-0.69%
201,975,000222,200,000268,072,000322,479,000323,313,000381,763,000432,968,000461,443,000450,003,000431,620,000469,053,000521,503,00020,311,000593,794,000592,198,000521,571,000692,843,000707,755,000642,234,000637,834,000
CFO
762m
+26.43%
298,067,000263,594,000370,507,000418,248,000418,263,000457,856,000497,374,000449,280,000484,876,000511,648,000560,293,000629,076,000697,640,000604,446,000643,087,000790,507,000747,274,000611,661,000602,809,000762,123,000
Dividend
Nov 26, 19960.16 USD/sh

Profile

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by life science, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
IPO date
Nov 17, 1995
Employees
8,200
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,958,387
0.07%
2,956,416
-0.52%
2,971,956
6.68%
Cost of revenue
930,947
2,067,512
2,082,398
Unusual Expense (Income)
NOPBT
2,027,440
888,904
889,558
NOPBT Margin
68.53%
30.07%
29.93%
Operating Taxes
117,034
94,009
130,091
Tax Rate
5.77%
10.58%
14.62%
NOPAT
1,910,406
794,895
759,467
Net income
637,834
-0.69%
642,234
-9.26%
707,755
2.15%
Dividends
Dividend yield
Proceeds from repurchase of equity
(13,541)
(70,277)
(583,260)
BB yield
0.06%
0.36%
2.82%
Debt
Debt current
25,537
105,650
76,429
Long-term debt
1,752,659
2,451,190
1,663,415
Deferred revenue
57,000
Other long-term liabilities
258,725
322,494
1,202,087
Net debt
1,452,841
2,156,031
1,239,290
Cash flow
Cash from operating activities
762,123
602,809
611,661
CAPEX
(142,481)
(160,632)
(183,456)
Cash from investing activities
(144,023)
(1,442,265)
(107,967)
Cash from financing activities
(696,675)
754,951
(509,633)
FCF
1,963,704
433,432
559,014
Balance
Cash
325,355
395,974
481,391
Long term investments
4,835
19,163
Excess cash
177,436
252,988
351,956
Stockholders' equity
9,635,002
9,018,328
8,368,639
Invested Capital
3,612,138
3,689,936
2,144,644
ROIC
52.33%
27.25%
36.67%
ROCE
53.50%
22.54%
36.46%
EV
Common stock shares outstanding
59,552
59,270
60,331
Price
370.98
12.68%
329.23
-3.90%
342.58
-8.06%
Market cap
22,092,601
13.22%
19,513,462
-5.59%
20,668,194
-10.57%
EV
23,545,442
21,669,493
21,907,484
EBITDA
2,219,265
1,054,809
1,019,981
EV/EBITDA
10.61
20.54
21.48
Interest
89,677
98,861
37,777
Interest/NOPBT
4.42%
11.12%
4.25%